Advanced search
Publication Cover
Scandinavian Journal of Urology and Nephrology Volume 45, 2011 - Issue 3
Submit an article Journal homepage
609
Views
41
CrossRef citations to date
0
Altmetric
UrologyOriginal Articles

Overexpression of fibroblast growth factor receptors FGFR1 and FGFR2 in renal cell carcinoma

Ilya Tsimafeyeu Kidney Cancer Research Bureau, Moscow, Russia, N.N. Blokhin Russian Cancer Research Center, Moscow, Russia, University of Toronto, Toronto, CanadaCorrespondence[email protected]
,
Lev Demidov Kidney Cancer Research Bureau, Moscow, Russia, N.N. Blokhin Russian Cancer Research Center, Moscow, Russia, University of Toronto, Toronto, Canada
,
Eugenia Stepanova Kidney Cancer Research Bureau, Moscow, Russia, N.N. Blokhin Russian Cancer Research Center, Moscow, Russia, University of Toronto, Toronto, Canada
,
Nigel Wynn Kidney Cancer Research Bureau, Moscow, Russia, N.N. Blokhin Russian Cancer Research Center, Moscow, Russia, University of Toronto, Toronto, Canada
&
Hung Ta Kidney Cancer Research Bureau, Moscow, Russia, N.N. Blokhin Russian Cancer Research Center, Moscow, Russia, University of Toronto, Toronto, Canada
Pages 190-195 | Received 11 Aug 2010, Accepted 21 Dec 2010, Published online: 18 Feb 2011

Citations (41)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Giandomenico Roviello, Silvia Paola Corona, Giovanni Bozza, Michele Aieta, Daniele Generali, Maria Grazia Rodriquenz, Anna Maria Mileo, Marco Imperatori, Anna Ianza, Raffaele Conca & Navid Sobhani. (2018) Lenvatinib for the treatment of renal cell carcinoma. Expert Opinion on Investigational Drugs 27:5, pages 507-512.
Read now
Chiara Ciccarese, Vincenzo Di Nunno, Rodolfo Montironi, Michelangelo Fiorentino, Matteo Brunelli, Giampaolo Tortora, Andrea Ardizzoni & Francesco Massari. (2016) The role of precision medicine for the treatment of metastatic renal cell carcinoma. Expert Review of Precision Medicine and Drug Development 1:4, pages 369-377.
Read now
Francesco Massari, Chiara Ciccarese, Matteo Santoni, Antonio Lopez-Beltran, Marina Scarpelli, Rodolfo Montironi & Liang Cheng. (2015) Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma. Expert Review of Anticancer Therapy 15:12, pages 1367-1369.
Read now
Shilpa Gupta & Mayer Fishman. (2011) Progress and contrasts of the development of tivozanib for therapy of kidney cancer. Expert Opinion on Pharmacotherapy 12:18, pages 2915-2922.
Read now

Articles from other publishers (37)

Qing Liu, Jiyu Huang, Weiwei Yan, Zhen Liu, Shu Liu & Weiyi Fang. (2023) FGFR families: biological functions and therapeutic interventions in tumors. MedComm 4:5.
Crossref
Xiaoyan liu, Mingxin Zhang, Chen Shao, Haidan Sun, Binbin Zhang, Zhengguang Guo, Jiameng Sun, Feng Qi, Yushi Zhang, Haitao Niu & Wei Sun. (2023) Blood- and Urine-Based Liquid Biopsy for Early-Stage Cancer Investigation: Taken Clear Renal Cell Carcinoma as a Model. Molecular & Cellular Proteomics 22:8, pages 100603.
Crossref
Linus Kruk, Medina Mamtimin, Attila Braun, Hans-Joachim Anders, Joachim Andrassy, Thomas Gudermann & Elmina Mammadova-Bach. (2023) Inflammatory Networks in Renal Cell Carcinoma. Cancers 15:8, pages 2212.
Crossref
Juan Jin, Yuhao Xie, Jin-Shi Zhang, Jing-Quan Wang, Shi-Jie Dai, Wen-fang He, Shou-Ye Li, Charles R. AshbyJr.Jr., Zhe-Sheng Chen & Qiang He. (2023) Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers. Drug Resistance Updates 67, pages 100929.
Crossref
Zheng Xu, Wu LuoLingfeng ChenZaishou ZhuangDaona YangJianchang QianZia A. KhanXinfu GuanYi WangXiaokun LiGuang Liang. (2022) Ang II (Angiotensin II)–Induced FGFR1 (Fibroblast Growth Factor Receptor 1) Activation in Tubular Epithelial Cells Promotes Hypertensive Kidney Fibrosis and Injury. Hypertension 79:9, pages 2028-2041.
Crossref
Revati Sharma, Elif Kadife, Mark Myers, George Kannourakis, Prashanth Prithviraj & Nuzhat Ahmed. (2021) Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma. Journal of Experimental & Clinical Cancer Research 40:1.
Crossref
Alexandru Nita, Sara P. Abraham, Pavel Krejci & Michaela Bosakova. (2021) Oncogenic FGFR Fusions Produce Centrosome and Cilia Defects by Ectopic Signaling. Cells 10:6, pages 1445.
Crossref
Jianhui Ma, Yan Song, Jianzhong Shou, Yuxian Bai, Hanzhong Li, Xiaodong Xie, Hong Luo, Xiubao Ren, Jiyan Liu, Dingwei Ye, Xianzhong Bai, Cheng Fu, Shukui Qin, Jinwan Wang & Ai-Ping Zhou. (2020) Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial. Frontiers in Oncology 10.
Crossref
Jee Young Park, Pil‐Jong Kim, Su‐Jin Shin, Jae‐Lyun Lee, Yong Mee Cho & Heounjeong Go. (2020) FGFR1 is associated with c‐MYC and proangiogenic molecules in metastatic renal cell carcinoma under anti‐angiogenic therapy. Histopathology 76:6, pages 838-851.
Crossref
Francesco Massari, Vincenzo Di Nunno, Matteo Santoni, Lidia Gatto, Claudia Caserta, Franco Morelli, Elena Zafarana, Francesco Carrozza, Alessandra Mosca, Veronica Mollica, Roberto Iacovelli, Roberto Sabbatini, Camillo Porta & Sergio Bracarda. (2019) Toward a genome-based treatment landscape for renal cell carcinoma. Critical Reviews in Oncology/Hematology 142, pages 141-152.
Crossref
Veronica Mollica, Vincenzo Di Nunno, Lidia Gatto, Matteo Santoni, Marina Scarpelli, Alessia Cimadamore, Antonio Lopez-Beltran, Liang Cheng, Nicola Battelli, Rodolfo Montironi & Francesco Massari. (2019) Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor. Cancers 11:6, pages 830.
Crossref
Viktor Grünwald, Thomas Powles, Toni K Choueiri, Thomas E Hutson, Camillo Porta, Masatoshi Eto, Cora N Sternberg, Sun Young Rha, Cixin S He, Corina E Dutcus, Alan Smith, Lea Dutta, Kalgi Mody & Robert J Motzer. (2019) Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale. Future Oncology 15:9, pages 929-941.
Crossref
Sumanta K. Pal, Paulo Bergerot, Nazli Dizman, Cristiane Bergerot, Jacob Adashek, Russell Madison, Jon H. Chung, Siraj M. Ali, Jeremy O. Jones & Ravi Salgia. (2018) Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma. European Urology 74:1, pages 124-128.
Crossref
D Chakraborty, V Benham, B Bullard, T Kearney, H C Hsia, D Gibbon, E Y Demireva, S Y Lunt & J J Bernard. (2017) Fibroblast growth factor receptor is a mechanistic link between visceral adiposity and cancer. Oncogene 36:48, pages 6668-6679.
Crossref
Masahiro Matsuki, Yusuke Adachi, Yoichi Ozawa, Takayuki Kimura, Taisuke Hoshi, Kiyoshi Okamoto, Osamu Tohyama, Kaoru Mitsuhashi, Atsumi Yamaguchi, Junji Matsui & Yasuhiro Funahashi. (2017) Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus. Cancer Science 108:4, pages 763-771.
Crossref
Shilong Ying, Xiaojing Du, Weitao Fu, Di Yun, Liping Chen, Yuepiao Cai, Qing Xu, Jianzhang Wu, Wulan Li & Guang Liang. (2017) Synthesis, biological evaluation, QSAR and molecular dynamics simulation studies of potential fibroblast growth factor receptor 1 inhibitors for the treatment of gastric cancer. European Journal of Medicinal Chemistry 127, pages 885-899.
Crossref
Shin Kumagai, Kei Ishibashi, Masao Kataoka, Toshiki Oguro, Yuichirou Kiko, Tomohiko Yanagida, Ken Aikawa & Yoshiyuki Kojima. (2016) Impact of Sulfatase‐2 on cancer progression and prognosis in patients with renal cell carcinoma. Cancer Science 107:11, pages 1632-1641.
Crossref
Hilary Glen. (2016) Lenvatinib therapy for the treatment of patients with advanced renal cell carcinoma. Future Oncology 12:19, pages 2195-2204.
Crossref
Chiara Ciccarese, Matteo Brunelli, Rodolfo Montironi, Michelangelo Fiorentino, Roberto Iacovelli, Daniel Heng, Giampaolo Tortora & Francesco Massari. (2016) The prospect of precision therapy for renal cell carcinoma. Cancer Treatment Reviews 49, pages 37-44.
Crossref
Ilya Tsimafeyeu, John Ludes-Meyers, Evgenia Stepanova, Frits Daeyaert, Dmitry Khochenkov, Jean-Baptiste Joose, Eliso Solomko, Koen Van Akene, Nina Peretolchina, Wei Yin, Oxana Ryabaya, Mikhail Byakhov & Sergei Tjulandin. (2016) Targeting FGFR2 with alofanib (RPT835) shows potent activity in tumour models. European Journal of Cancer 61, pages 20-28.
Crossref
Thai H Ho, Xian-De Liu, Yanqing Huang, Carla L Warneke, Marcella M Johnson, Anh Hoang, Pheroze Tamboli, Fen Wang & Eric Jonasch. (2015) The impact of FGFR1 and FRS2α expression on sorafenib treatment in metastatic renal cell carcinoma. BMC Cancer 15:1.
Crossref
Ilya Tsimafeyeu & Gennady Bratslavsky. (2015) Fibroblast Growth Factor Receptor 1 as a Target for the Therapy of Renal Cell Carcinoma. Oncology 88:6, pages 321-331.
Crossref
C. Lance Cowey & Thomas E. Hutson. 2015. Renal Cell Carcinoma. Renal Cell Carcinoma 349 375 .
Li Tan, Jun Wang, Junko Tanizaki, Zhifeng Huang, Amir R. Aref, Maria Rusan, Su-Jie Zhu, Yiyun Zhang, Dalia Ercan, Rachel G. Liao, Marzia Capelletti, Wenjun Zhou, Wooyoung Hur, NamDoo Kim, Taebo Sim, Suzanne Gaudet, David A. Barbie, Jing-Ruey Joanna Yeh, Cai-Hong Yun, Peter S. Hammerman, Moosa Mohammadi, Pasi A. Jänne & Nathanael S. Gray. (2014) Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors. Proceedings of the National Academy of Sciences 111:45, pages E4869-E4877.
Crossref
ZUHU YU, LIANGCHAO NI, DUQUN CHEN, ZHENGMING SU, WENSHUI YU, QIANG ZHANG, YADONG WANG, CAILING LI, YAOTING GUI & YONGQING LAI. (2014) Expression and clinical significance of RCDG1 in renal cell carcinoma: A novel renal cancer-associated gene. Molecular Medicine Reports 10:3, pages 1583-1589.
Crossref
Han Kiat Ho, Angie Hui Ling Yeo, Tse Siang Kang & Boon Tin Chua. (2014) Current strategies for inhibiting FGFR activities in clinical applications: opportunities, challenges and toxicological considerations. Drug Discovery Today 19:1, pages 51-62.
Crossref
Roberto Pili, Eric Kauffman & Ronald Rodriguez. 2014. Abeloff's Clinical Oncology. Abeloff's Clinical Oncology 1416 1444.e5 .
Ilya Tsimafeyeu, Elina Zaveleva, Evgenia Stepanova & Walter Low. (2013) OM-RCA-01, a novel humanized monoclonal antibody targeting fibroblast growth factor receptor 1, in renal cell carcinoma model. Investigational New Drugs 31:6, pages 1436-1443.
Crossref
Stephen L. Richey & Thomas E. Hutson. (2013) Angiopoietins and Non–Vascular Endothelial Growth Factor Antiangiogenic Targets in Advanced Renal Cell Carcinoma. The Cancer Journal 19:4, pages 307-310.
Crossref
Martin H. Voss, James J. Hsieh & Robert J. Motzer. (2013) Novel Approaches Targeting the Vascular Endothelial Growth Factor Axis in Renal Cell Carcinoma. The Cancer Journal 19:4, pages 299-306.
Crossref
Lu Lv, Fengxian Huang, Haiping Mao, Ming Li, Xiaoyan Li, Man Yang & Xueqing Yu. (2018) MicroRNA-21 is Overexpressed in Renal Cell Carcinoma. The International Journal of Biological Markers 28:2, pages 201-207.
Crossref
A. Salman, E. Shufan, L. Zeiri & M. Huleihel. (2013) Detection and identification of cancerous murine fibroblasts, transformed by murine sarcoma virus in culture, using Raman spectroscopy and advanced statistical methods. Biochimica et Biophysica Acta (BBA) - General Subjects 1830:3, pages 2720-2727.
Crossref
Friederike Göke, Alina Franzen, Roopika Menon, Diane Goltz, Robert Kirsten, Diana Boehm, Wenzel Vogel, Antonia Göke, Veit Scheble, Joerg Ellinger, Ulrich Gerigk, Falko Fend, Patrick Wagner, Andreas Schroeck & Sven Perner. (2012) Rationale for Treatment of Metastatic Squamous Cell Carcinoma of the Lung Using Fibroblast Growth Factor Receptor Inhibitors. Chest 142:4, pages 1020-1026.
Crossref
Shanshan Sun, Yongdong Jiang, Guoqiang Zhang, Hongtao Song, Xianyu Zhang, Youxue Zhang, Xiaoshuan Liang, Qian Sun & Da Pang. (2011) Increased expression of fibroblastic growth factor receptor 2 is correlated with poor prognosis in patients with breast cancer. Journal of Surgical Oncology 105:8, pages 773-779.
Crossref
YA-MIN CHENG, CHENG-YANG CHOU, YI-CHIANG HSU, MING-JENN CHEN & LIH-YUH C. WING. (2011) The role of human papillomavirus type 16 E6/E7 oncoproteins in cervical epithelial-mesenchymal transition and carcinogenesis. Oncology Letters 3:3, pages 667-671.
Crossref
C. Lance Cowey & Thomas E. Hutson. 2012. Renal Cell Carcinoma. Renal Cell Carcinoma 135 160 .
Sumanta Kumar Pal, Karen Reckamp, Hua Yu, Robert A. Figlin, Robert A. Figlin & Robert A. Figlin. 2012. Renal Cell Carcinoma. Renal Cell Carcinoma 239 252 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.